Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

AFT Pharmaceuticals (NZX: AFT)

Last close As at 21/11/2024

NZD2.65

▲ 0.11 (4.33%)

Market capitalisation

NZD278m

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

AFT Pharmaceuticals is a multi-product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offer it a competitive advantage in a fragmented industry.

Latest Insights

View More

Healthcare | Flash note

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Healthcare | Flash note

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

Healthcare | edison tv

AFT Pharmaceuticals – executive interview

Healthcare | Flash note

AFT Pharmaceuticals — Hikma partnership expands to include Combogesic
AFT-Pharmaceuticals_resized
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • David Flacks

    Chairman

  • Dr Hartley Atkinson

    CEO

  • Malcolm Tubby

    Chief Financial Officer

  • Michael Weinmann

    Member of the Board of Directors

  • Nathan D. Hukill

    Member of the Board of Directors

Balance Sheet

Forecast net debt (NZ$m)

7.6

Forecast gearing ratio (%)

7

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (21.4) (19.6) (22.1)
Relative (20.8) (19.7) (29.3)
52 week high/low 3.8/2.4

Financials

AFT Pharmaceuticals is a profitable New Zealand-based specialty pharmaceutical company that sells over 150 proprietary branded and generic products through its own salesforce in New Zealand and Australia, with offices across the globe to handle its growing export business. AFT reported strong FY24 results, with 24.8% y-o-y top-line growth, and targets an FY25 operating profit of NZ$22–25m, excluding any potential licensing income. It launched Maxigesic IV in the US in February 2024, and continues to focus on portfolio expansion and geographical diversification, including signing an exclusive licence agreement in China in September 2024. It recently announced a new R&D candidate for keloid and hypertrophic scarring, manufacturing agreements for Maxigesic Rapid and Crystaderm, partnership expansion with Hikma (to expand in the Middle East), entry into the UK and a licensing deal for Maxigesic IV in Brazil.

Y/E Mar Revenue (NZ$m) EBITDA (NZ$m) PBT (NZ$m) EPS (c) P/E (x) P/CF (x)
2023A 156.6 21.4 16.7 11.0 24.1 26.1
2024A 195.4 26.2 23.0 15.8 16.8 17.8
2025E 232.4 26.6 23.6 16.5 16.1 17.1
2026E 278.3 43.4 40.8 28.3 9.4 9.7

Research

Flash note

Healthcare

AFT Pharmaceuticals — Maxigesic IV reaches the Chinese shores

edison tv

Healthcare

AFT Pharmaceuticals – executive interview

Healthcare

Flash note

AFT Pharmaceuticals — H125 profitability weighed down by one-offs
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free